Ray Dalio's KRYS Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 46,367 shares of Krystal Biotech, Inc. (KRYS) worth $11.98 M, representing 0.05% of the portfolio. First purchased in 2025-Q3, this short-term holding has been held for 3 quarters.
Based on 13F filings, Ray Dalio has maintained this position in KRYS for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 36,352 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Krystal Biotech (KRYS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Krystal Biotech (KRYS) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +36,352 | Add 362.98% | 46,367 | $258.32 |
| Q4 2025 | +292 | Add 3.00% | 10,015 | $246.54 |
| Q3 2025 | +9,723 | New Buy | 9,723 | $176.53 |
Ray Dalio's Krystal Biotech Investment FAQs
Ray Dalio first purchased Krystal Biotech, Inc. (KRYS) in Q3 2025, acquiring 9,723 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Krystal Biotech, Inc. (KRYS) for 3 quarters since Q3 2025.
Ray Dalio's largest addition to Krystal Biotech, Inc. (KRYS) was in Q1 2026, adding 46,367 shares worth $11.98 M.
According to the latest 13F filing for Q1 2026, Ray Dalio's firm, Bridgewater Associates, Lp, owns 46,367 shares of Krystal Biotech, Inc. (KRYS), valued at approximately $11.98 M.
As of the Q1 2026 filing, Krystal Biotech, Inc. (KRYS) represents approximately 0.05% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in Krystal Biotech, Inc. (KRYS) was 46,367 shares, as reported at the end of Q1 2026.